International guidelines suggest hepatitis C virus (HCV) eradication by direct-acting antivirals (DAAs) after first-line immunochemotherapy (I-CT) in patients with HCV-positive diffuse large B-cell lymphoma (DLBCL), although limited experiences substantiate this recommendation. Moreover, only a few data concerning concurrent administration of DAAs with I-CT have been reported.
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas
Piazza, Francesco;PASSAMONTI, FRANCESCO;
2018
Abstract
International guidelines suggest hepatitis C virus (HCV) eradication by direct-acting antivirals (DAAs) after first-line immunochemotherapy (I-CT) in patients with HCV-positive diffuse large B-cell lymphoma (DLBCL), although limited experiences substantiate this recommendation. Moreover, only a few data concerning concurrent administration of DAAs with I-CT have been reported.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
onco12775.pdf
accesso aperto
Tipologia:
Published (publisher's version)
Licenza:
Accesso libero
Dimensione
757.99 kB
Formato
Adobe PDF
|
757.99 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
